Elsevier

Vaccine

Volume 29, Issue 37, 26 August 2011, Pages 6163-6166
Vaccine

Short communication
Immunogenicity of conjugate Meningococcus C vaccine in pediatric solid organ transplant recipients

https://doi.org/10.1016/j.vaccine.2011.06.033Get rights and content

Abstract

The present study was aimed to evaluate the immunogenicity of a single dose of conjugate Meningococcus C (Men C) vaccine by analyzing the serum bactericidal antibody (SBA) titers in 10 pediatric solid organ transplant (SOT) patients. Four patients showed a delayed immune response after 1 month, but all patients demonstrated an increase of SBA titers after vaccination. A significant decrease of SBA titers was seen after 6 months. However, all patients maintained protective SBA titers (≥1:8) despite rapidly waning titers. For patients with significantly decreasing titers, a booster dose may be discussed with close monitoring of SBA titers over time.

Introduction

Fortunately, the improvement of surgical techniques, of immunosuppressive regimens and of clinical monitoring strategies allows pediatric and adolescent solid organ transplantation (SOT) patients an almost normal life quality with school attendance and travel activities. However, these life-style factors bear also the increased risk of contacts with Men C carriers and infected individuals. An impaired antibody production after vaccinations have been described in SOT patients [1], [2], [3] and in children on dialysis considered for kidney transplantation [3], [4]. So far, no prospective data exist on immunogenicity and safety of conjugated Meningococcus C (Men C) vaccination in pediatric SOT patients or patients with renal insufficiency. Severe cases of meningococcal disease were reported in immunocompromised patients [5]. Some experience with the administration of conjugate vaccines in immunocompromised patients exist from studies with vaccinations against Streptococcus pneumoniae in SOT recipients which was proven to induce protective antibody levels [6], [7], [8], [9], [10], and with conjugate Men C vaccination in hematopoetic stem cell transplantation [11] with 100% of patients achieving humoral protection against Men C. However, 13 of 25 leukemia patients were found to be bactericidal non-responders to conjugated Men C vaccination [12]. Despite the uncertain beneficial effect of Men C vaccination in immunocompromised children, the risk of relapses in chronic kidney disease, such as nephrotic syndrome by conjugate Men C vaccine, has been discussed controversially [13], [14]. All the more, immunogenicity and safety aspects in risk populations are important for the administration of newly licensed conjugate vaccines addressing not only Men C, but also infections with other serogroups, such as A, Y or W135.

The serum bactericidal assay (SBA) titer against Men C is the generally accepted surrogate of protection against Men C-induced disease [15], [16]. Evidence of an antibody response to the vaccine was defined by a SBA titer of ≥1:8 [17]. In healthy children and also preterm infants, vaccination with NeisVac-C (Baxter, Vienna, Austria) has been proven to be well tolerated [17], [18], [19], [20].

The present single-center study was aimed to evaluate the immunogenicity and safety of vaccinating pediatric SOT patients with conjugated Men C vaccine (NeisVac-C) by analyzing the SBA titers after vaccination.

Section snippets

Study population

In 2007, 10 patients (chronological age: mean 156 ± 54 months, range 70–216) were prospectively included based on following inclusion criteria: end-stage renal failure (after Schwartz formular <30 ml/min/m2), kidney or liver transplantation, normal age-adjusted serum immunoglobuline values, normal age-adjusted absolute lymphocyte counts (2.47 × 103/μl ± 0.86, range 1.10–3.43) with a CD4/CD8 ratio between 1.3 and 2.5 and normal age-adjusted proportions of CD19 + B cells (24 ± 12%, range 11–31). Only

Immunogenicity

The immunogenicity of conjugate Men C vaccination was assessed in all SOT patients. Four patients, namely, patient 1 (after 2 months), 3 (after 1 month), 4 (after 1 month) and 7 (after 3 months) showed a slightly delayed increase of SBA titers in the first weeks after vaccination. In 8 patients, SBA titers were evaluated 3 months after vaccination. All of them demonstrated a significant increase of SBA titers at least 3 months after vaccination (Fig. 1) (day 0 versus month 3: p < 0.001). For all

Discussion

The present case series revealed a variable response to conjugate Men C vaccine in pediatric SOT patients who had received a single dose shortly before or after transplantation. Following the generally accepted definition of protective SBA titers [16], all patients demonstrated an increase of SBA titers after vaccination and maintained protective SBA titers at least 18 months after a single dose of conjugate Men C vaccine, with one patient not completing the follow-up course. The data were

Acknowledgement

The study was supported by a research grant by Baxter, Vienna, Austria. We like to thank Dr. Robert Petermann for critical discussion of the paper. Conflict of interest: All authors report no conflicts of interest relevant to this article. Funding: The National Reference Laboratory for Meningococci in Würzburg, Germany, is funded by the Robert Koch-Institute. The expert technical assistance by Angelika Külsheimer and Christin Staar is gratefully acknowledged.

References (28)

  • M. Barton et al.

    Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity

    Pediatr Infect Dis J

    (2009)
  • S. Vieira et al.

    Evaluation of antibody response to heptavalent pneumococcal conjugate vaccine in pediatric chronic kidney disease

    Pediatr Nephrol

    (2009)
  • D. Kumar et al.

    A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients

    Clin Infect Dis

    (2008)
  • S. Patel et al.

    Revaccination with measles, tetanus, poliovirus, haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation

    Clin Infect Dis

    (2007)
  • Cited by (12)

    • Vaccination issues for transplantation and chemotherapy

      2020, Pediatric Transplant and Oncology Infectious Diseases
    • Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus

      2017, Jornal de Pediatria
      Citation Excerpt :

      Vaccine-induced antibodies also may wane more quickly in persons with HIV than in healthy individuals, indicating that immune reconstitution was not sufficient to ensure long-term protection and highlighting the importance of evaluating long-term immunogenicity to meningococcal vaccines and factors that may be associated with a better response.8,9 The persistence of antibodies after meningococcal serogroup C (MCC) conjugate vaccines has been studied in many high-risk populations with different degrees of immunosuppression, but there are few studies in HIVI.10–12 The aims of this study were: (1) to assess the persistence of serum bactericidal antibody against MCC, using human complement (hSBA) in HIVI children and adolescents, 12–18 months after a single dose of MCC, and compared with HIVU participants; and (2) to evaluate factors associated with antibody persistence.

    • Travel medicine and the solid-organ transplant recipient

      2013, Infectious Disease Clinics of North America
      Citation Excerpt :

      However, 40% had a delayed immune response, which may be relevant to the timing of vaccination before a trip to an endemic region. There was a significant decrease in titers after 6 months, which is important because the standard recommendations for revaccination of those at continued risk is after 5 years.28 It may be reasonable to check titers and give an earlier booster if protective levels are no longer present.

    View all citing articles on Scopus
    View full text